Defensive Publication: Sequenced Short-Course Auranofin as an Adjunct Macrofilaricide Timing-Integrated with Mass-Drug-Administration Microfilaricides, with a Low-Resource Gold-Toxicity Monitoring Protocol, for Lymphatic Filariasis and Onchocerciasis (Method of Use)
Description
Enabling defensive publication of 'Sequenced Short-Course Auranofin as an Adjunct Macrofilaricide Timing-Integrated with Mass-Drug-Administration Microfilaricides, with a Low-Resource Gold-Toxicity Monitoring Protocol, for Lymphatic Filariasis and Onchocerciasis (Method of Use)' (internal ref PDX-D05). Intentional public disclosure to establish prior art under 35 U.S.C. § 102(a)(1) and to keep the subject matter free for anyone to produce. Method-of-use disclosure for generic off-patent auranofin as an adjunct macrofilaricide, timing-sequenced after existing WHO mass-drug-administration microfilaricides (ivermectin/albendazole/IDA), with a field-deployable low-resource gold-toxicity monitoring protocol. The already-public preclinical macrofilaricidal activity (Bulman 2015, PMID 25700363) and human dose-finding (Capparelli/Reed 2017, PMID 27821451) are cited as prior art and NOT re-claimed; only the MDA-sequencing/timing protocol and the low-resource monitoring protocol are disclosed as the novel contribution. Dedicated to the public domain to keep this off-patent use free.